Education
About Us
Working with TipRanks
Follow Us
Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
CNTB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $2.86
Previous CloseN/A
Volume1.98K
Average Volume (3M)218.76K
Market Cap
$103.93M
Enterprise Value-$16.51M
Total Cash (Recent Filing)$71.77M
Total Debt (Recent Filing)$870.00K
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding55,721,657
10 Day Avg. Volume156,049
30 Day Avg. Volume218,759
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-8.42
Enterprise Value/Gross Profit-9.29
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$6.83Price Target Upside294.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical TrialsConnect Biopharma initiated parallel Phase 2 Seabreeze STAT proof-of-concept trials in acute asthma and COPD for their lead asset rademikibart, which may demonstrate significant efficacy.
Financial OpportunitiesConnect Biopharma is eligible to receive up to $110 million in milestone payments and royalties from Simcere, highlighting a significant financial opportunity upon achieving certain milestones.
Market PresenceThe company's restructuring to focus on the US market, including relocating its headquarters to San Diego, is aimed at enhancing its market presence and operational efficiency.
Bears Say
Financing RequirementsFinancing requirements for the business assume cash runway into 2027 and approximately $150M additional financing needed through 2038.
RisksRisks include safety signals emerge with any of the company’s clinical or preclinical programs, efficacy from clinical programs is lower than expected, or the company’s studies do not achieve statistical significance.
Safety And Efficacy ConcernsFDA acknowledged the unmet need for reducing recurrent exacerbations following an acute exacerbation of asthma or COPD which occurs in up to 50% of cases.
Connect Biopharma Holdings News
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.51 and its highest was $2.86 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $103.93M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Mar 26, 2026 which is in 211 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on Aug 13, 2025. The company reported -$0.231 earnings per share for the quarter, missing the consensus estimate of -$0.221 by -$0.01.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 55,721,657 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of -$0.231 in its last earnings report, missing expectations of -$0.221. Following the earnings report the stock price went up 3.965%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
Connect Biopharma Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.83 (294.80% Upside)
$6.83 (294.80% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.97%
12-Months-Change
Fundamentals
Return on Equity
-58.89%
Trailing 12-Months
Asset Growth
-15.87%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
CNTB Stock 12 Month Forecast
Average Price Target
$6.83
▲(294.80% Upside)
Technical Analysis
Dyadic International
―
X4 Pharmaceuticals
―
Reviva Pharmaceuticals Holdings
―
PepGen Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
11.70%
Insiders
0.04% Mutual Funds
3.52% Other Institutional Investors
96.44% Public Companies and
Individual Investors